课题基金 / 基金详情

IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA

IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
IDEC Y2B8 放射免疫治疗 B 细胞非霍奇金淋巴瘤
批准号：
6304157
负责人：
Leo I. Gordon
金额：
$2.05万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6304157
关键词：
B lymphocyte antineoplastics clinical research combination cancer therapy human subject human therapy evaluation monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy nonHodgkin's lymphoma platelets radiotracer

项目摘要

项目成果

Leo I. Gordon的其他基金

相似基金

相关文献

中文摘要
翻译
IDEC Pharmaceuticals评价IDEC-Y2 B8疗效和安全性的现行方案是一项比较Rituxan单药治疗与Rituxan和放射性标记单克隆抗体治疗的随机化研究。 它仅限于血小板计数超过150，000的患者。拟定研究IDEC 106-05是一项在血小板计数100- 150，000的患者中使用Rituxan和IDEC Y2 B8的非随机化研究。
英文摘要
The current IDEC Pharmaceuticals protocol evaluating the efficacy and safety of IDEC-Y2B8 is a randomized study comparing Rituxan alone to Rituxan and radiolabelled monoclonal antibody therapy. It is restricted to patients who have platelet counts above 150,000. The proposed study IDEC 106-05 is a non-randomized study using Rituxan and IDEC Y2B8 for patients with platelet counts from 100-150,000.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
海外基金